** Shares of genetic testing firm Natera NTRA.O fall 2.3% to $154.80 premarket, as a $96 mln jury verdict against rival CareDx CDNA.O gets overturned
** U.S. District Judge Colm Connolly rules that the patents Natera accused CareDx of infringing were invalid, dismissing Natera's 2024 trial win over patent rights in DNA testing technology for kidney transplants
** Natera plans to appeal the decision and pursue "all available remedies"
** CareDx's attorney said the decision was "the right outcome on the law and for organ transplant patients"
** A jury had previously said that CareDx infringed one of the patents and awarded Natera $96.3 million in damages, but the judge's decision overturned this verdict
** NTRA more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.